Atlas Trials

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

Clinical trial NCT06592170 · RECRUITING

Trial details

NCT number
NCT06592170
Sponsor
The First Hospital of Jilin University
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lymphoma
Start date
2024-08-13
Primary completion
2025-08-13
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.